Gianni Scappaticci, PharmD, BCOP, discusses key considerations in therapy selection, limitations of current treatments, and the evolving role of pharmacists in managing chronic graft-versus-host disease (cGVHD) through patient education, adherence support, and integration of emerging therapies.